Tuesday, April 30, 2019
Immunomedics is going to China
In what is billed as the largest single-asset pharma license agreement in Chinese history, sacituzumab govetecan is going to China. This deal gives Immunomedics $65M upfront with another $60M based on FDA approval.
This money is probably timed well and will go a long way towards getting them back on track after a rough couple of months based on both their BLA rejection from the FDA and the departure of their CEO. Hopefully this is the first step back on track, and back towards their FDA approval and beyond